SION
Sionna Therapeutics, Inc.42.89
+0.13+0.3%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.91BP/E (TTM)
-Basic EPS (TTM)
-1.80Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Sionna narrowed its Q3 operating loss to $23.8M from $28.0M y/y, as R&D expenses dropped 35% to $16.0M—absent last year's $13.6M IPR&D hit from the AbbVie deal—while G&A rose to $7.8M on public company costs and hiring; nine-month net loss widened to $54.8M from $45.8M y/y amid pipeline ramp. Interest income boosted other income 39% y/y to $3.5M. Cash and marketable securities swelled to $325.0M post-February IPO, funding ops into 2028. Vertex holds dominant CF market share.
8-K
Launches CF trials, bolsters cash
Sionna Therapeutics initiated PreciSION CF Phase 2a trial of SION-719 as CF add-on to standard of care and Phase 1 dual combo trial of SION-451, both with topline data mid-2026. R&D expenses dropped to $16M from $24.6M year-over-year, driving net loss to $20.3M. Cash hit $325M, funding ops into 2028. Pipeline accelerates.
8-K
Positive Phase 1 CF drug data
Sionna Therapeutics reported positive Phase 1 data for NBD1 stabilizers SION-719 and SION-451, showing good tolerability and strong pharmacokinetics in over 200 healthy volunteers. The company plans Phase 2a initiation for SION-719 in CF patients this half, with topline results mid-2026, while advancing SION-451 combos. Cash stands at $337.3 million, funding ops into 2028. Net loss hit $18.1 million amid rising R&D costs. Progress fuels CF therapy hopes.
10-Q
Q2 FY2025 results
Sionna Therapeutics posted a Q2 net loss of $18.1 million, up 111% y/y from $8.6 million, as research and development expenses climbed 87% to $15.4 million on ramped-up clinical programs for NBD1 stabilizers SION-719 and SION-451, while general and administrative costs rose 113% to $6.5 million amid public company scaling. YTD net loss widened to $34.6 million from $20.4 million, with operating cash use hitting $34.4 million; free cash flow not disclosed in the 10-Q. Yet cash swelled to $337.3 million post-February IPO, funding operations into 2028. Positive Phase 1 data advanced both candidates to next trials in H2 2025. Vertex's dominance in CF therapies poses a steep competitive hurdle.
8-K
Annual meeting elects directors
Sionna Therapeutics held its annual stockholder meeting on June 12, 2025, electing Joshua Resnick, M.D., M.B.A., Bruce Booth, D.Phil., and Lucian Iancovici, M.D., as Class I directors for terms until 2028, with each receiving over 42 million votes for amid minimal opposition. Stockholders unanimously ratified Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2025. Board continuity solidified. No strategic shifts disclosed.
ARCT
Arcturus Therapeutics Holdings
7.13-0.12
BEAM
Beam Therapeutics Inc.
26.76-0.07
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
CYCN
Cyclerion Therapeutics, Inc.
1.53-0.07
IONS
Ionis Pharmaceuticals, Inc.
78.37-1.39
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
SLXN
Silexion Therapeutics Corp
2.61+0.05
SRPT
Sarepta Therapeutics, Inc.
22.31+0.76
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75